For the second quarter ending June 30 2023, HEALTHWAY MEDICAL ($SGX:5NG) reported total revenue of SGD 80.9 million, an increase of 1.2% from the same period the year prior, and net income of SGD 3.7 million, a 50.5% increase from the preceding year.
GoodWhale has conducted an evaluation of HEALTHWAY MEDICAL‘s financials, and based on the Star Chart, it appears that the company is strong in liquidity, medium in asset, growth, profitability, and weak in dividend. Given this information, investors who seek moderate growth may be interested in investing in HEALTHWAY MEDICAL. Additionally, the company has a high health score of 7/10, which indicates that its cashflows and debt are sufficient enough to safely ride out any crisis without the risk of bankruptcy. As such, investors who are looking for a steady investment with minimal risk may be interested in HEALTHWAY MEDICAL. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Healthway Medical. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Healthway Medical. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Healthway Medical. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Healthway Medical are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company has been providing quality healthcare services to its patients since its establishment in 1999. Healthway Medical Corp Ltd operates in a competitive environment, with other healthcare service providers such as Life Healthcare Group Holdings Ltd, Gushengtang Holdings Ltd, and Eukedos SpA providing similar services. Despite the competition, Healthway Medical Corp Ltd remains committed to providing the best possible healthcare services to its customers.
– Life Healthcare Group Holdings Ltd ($BER:L53)
Life Healthcare Group Holdings Ltd is a South African-based private healthcare provider that operates in South Africa, Botswana, Mozambique, Namibia, and Swaziland. It operates a network of acute care facilities, including hospitals, day-clinics, and specialty clinics. As of 2023, the company has a market capitalization of 1.48 billion and a Return on Equity of 10.61%. The market cap shows the total value of the shares outstanding of Life Healthcare Group Holdings Ltd, while the ROE measures how well the company has generated profits relative to its shareholders’ investment. The high ROE demonstrates that Life Healthcare Group is an efficient and profitable company with strong financial performance.
– Gushengtang Holdings Ltd ($SEHK:02273)
Gushengtang Holdings Ltd is a Chinese-based company involved in the manufacture and sale of various agricultural products. As of 2023, the company has a market capitalization of 9.7 billion dollars, making it one of the larger agricultural companies in the world. The company also boasts an impressive Return on Equity (ROE) of 10.07%, indicating the company is profitable and generating shareholder value. Through its operations, Gushengtang Holdings Ltd strives to provide quality services and products for its customers while also providing rewarding investment opportunities for its shareholders.
Eukedos SpA is a publicly traded Italian tech company that provides IT services and solutions to businesses. As of 2023, the company’s market capitalization stands at 23.42M, indicating its presence in the industry. Furthermore, its return on equity (ROE) of 9.49% reflects its strong financial performance compared to other companies in the same sector. The company has been able to remain competitive in the industry by providing customers with innovative solutions and services. It is also actively investing in research and development to stay ahead of the competition.
Healthway Medical reported a modest 1.2% increase in total revenue for the second quarter of 2023, reaching SGD 80.9 million. Net income also saw a notable 50.5% surge to SGD 3.7 million, compared to the same time period in the prior year. Investors will take comfort from the relatively steady top-line growth, as well as the significant jump in net income, which suggests the company is managing its costs well and increasing its profitability. With these encouraging figures in the latest financial report, Healthway Medical appears to be a sound investment opportunity in the near term.